试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-19
Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B
编号:NCT05760703登记状态:提前终止企业 / 申办者:Staidson (Beijing) Biopharmaceuticals Co., Ltd
药物 / 成分:STSG-0002 Injection
登记的停止原因(原文):The preliminary effectiveness data observed at present did not meet the expectations, the benefit of the subjects receiving the experimental drug was limited.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-19
To Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B
编号:NCT05760781登记状态:提前终止企业 / 申办者:Staidson (Beijing) Biopharmaceuticals Co., Ltd
药物 / 成分:STSG-0002 Injection
登记的停止原因(原文):The preliminary effectiveness data observed at present did not meet the expectations, the benefit of the subjects receiving the experimental drug was limited.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-18
Survival Prolongation by Rationale Innovative Genomics
编号:NCT03386929登记状态:提前终止企业 / 申办者:Worldwide Innovative Network Association
药物 / 成分:Avelumab、Axitinib、Palbociclib
登记的停止原因(原文):The SPRING trial had to be early terminated at the end of the Phase 1 portion of the study due to the absence of funding necessary for the performance of the Phase 2.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-18
A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1
编号:NCT03837353登记状态:提前终止企业 / 申办者:NYU Langone Health
药物 / 成分:DKN-01、Docetaxel
登记的停止原因(原文):Terminated early due to slow accrual in the context of changing practice patterns.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-18
A Safety, Tolerability, and Efficacy Study of IBI314 in Ambulatory Patients With COVID-19
编号:NCT05162365登记状态:提前终止企业 / 申办者:Innovent Biologics (Suzhou) Co. Ltd.
药物 / 成分:IBI314、Placebo
登记的停止原因(原文):The company decision that terminated the further develop of the molecule and had notified FDA about the termination as well.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-15
Study of ORIC-101 in Combination With Anticancer Therapy
编号:NCT03928314登记状态:提前终止企业 / 申办者:ORIC Pharmaceuticals
药物 / 成分:ORIC-101、Nab-paclitaxel
登记的停止原因(原文):IND Withdrawn
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-15
Study of ORIC-101 in Combination With Enzalutamide
编号:NCT04033328登记状态:提前终止企业 / 申办者:ORIC Pharmaceuticals
药物 / 成分:ORIC-101、enzalutamide 40 MG oral capsule [Xtandi]
登记的停止原因(原文):IND Withdrawn
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-15
Genetic and Dietary Predictors of Anti-platelet Response
编号:NCT04456608登记状态:提前终止企业 / 申办者:University of Washington
药物 / 成分:Aspirin
登记的停止原因(原文):Funding ended before the study could be completed,
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-15
Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia
编号:NCT04543279登记状态:提前终止企业 / 申办者:Washington University School of Medicine
药物 / 成分:Fostamatinib、Ruxolitinib
登记的停止原因(原文):Low accrual
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-14
Omega-3 Fatty Acids as an Adjunctive Therapy for Stimulants in Children With ADHD
编号:NCT01778647登记状态:提前终止企业 / 申办者:Antonios Likourezos
药物 / 成分:Stimulants plus Lovaza、Stimulants plus placebo
登记的停止原因(原文):Co-Investigators left the Institution.
查看官方原始记录 ↗